Figure 6.

InVivo miR-155 Carried by Exosomes in Tumors and Angiogenesis

(A) A flow chart demonstrating the in vivo experimental design and relevant morphology. (B) Tumor tissues excised from tumor-implanted mice in three groups (n = 5). (C–E) Quantitative analysis of xenografted tumor diameter (C), volume (D), and weight (E) (n = 5). (F) FOXO3a expression (left) in implanted tumors (n = 5) and the corresponding quantification (right). (G) qRT-PCR analysis of miR-155 in implanted tumors (n = 5). (H) The level of miR-155 in exosomes that were isolated from the sera of tumor-implanted mice (n = 5). (I) Immunohistochemical analysis of the paraffin-embedded tumor tissues using a CD31 antibody (n = 5; CD31 is widely used to demonstrate the existence of endothelial tissue and to assess tumor angiogenesis) and the corresponding quantification. (J) Survival analysis of GC patients with high or low miR-155 expression from the tumor database (http://www.oncolnc.org/). *p < 0.05, **p < 0.01, ***p < 0.001.